Osteo-Site Vertebral Balloon and Complex VCF Treatment Toolbox Launches

Osteo-Site Vertebral Balloon for vertebral augmentation has launched. The news was announced today by IZI Medical Products, a manufacturer of interventional radiology devices.

Osteo-Site Vertebral Balloon completes IZI’s offering of Vertebral Compression Fracture (“VCF”) treatment options, which include Osteo-Site Vertebroplasty, Osteo-Site Balloon Kyphoplasty, Blazer Curved Needle Augmentation, and Kiva PEEK Implant-based augmentation.

“We want to enable our physicians to choose the most clinically appropriate solution for their patients when treating vertebral compression fractures,” said Greg Groenke, CEO, IZI Medical. “We have created an integrated portfolio of VCF treatment devices with the ability to switch between different treatment options with ease.”

“IZI has completed the VCF toolbox: Kiva for metastatic VCF’s, Blazer Curved Needle for targeted cement deployment in sclerotic bone and blastic metastases, and now Osteo-site Balloon and curved needle for osteoporotic fractures. IZI has made it simple to switch between all of them which gives me intra-operative flexibility,” said Dr. Kieran Murphy, Professor of Radiology at University Health Network Toronto.

The new Osteo-site Vertebral Balloon is designed to create a cavity within the vertebral body. Currently, the balloon is available in 10G and 11G sizes. “The Osteo-site balloon will be paired with our Duro-Ject Injector, which provides maximum control and feedback during injection and minimizes radiation exposure with a long flexible tubing,” said Jovie Soriano, SVP Marketing and Business Development, IZI Medical. “We have also made improvements to our Murphy access needles based on physician feedback that will be included in the Osteo-Site Balloon kit.”

IZI Medical’s VCF portfolio will be supported by a dedicated sales team of direct representatives and independent distributors to drive market penetration in the United States, followed by expansion into Europe.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy